OpenLobby.EU
Explore

Seqens

Seqens

Seqens is an integrated global leader in pharmaceutical solutions and specialty ingredients, delivering outstanding performance, unrivalled market responsiveness and custom-made solutions to its customers.

Lobbying Activity

Response to Evaluation and revision of the general pharmaceutical legislation

26 Apr 2021

The unprecedented health crisis that is particularly affecting Europe has highlighted our continent's shortcomings in terms of health sovereignty. As the cradle of pharmaceutical synthesis, Europe has gradually lost its capacity to develop new production processes. Today, more than 80% of Europe's dependence on Asia for the production of molecules that are often old, with low added value but absolutely critical for our fellow citizens. The vulnerability of essential medicines value chains therefore makes it essential that appropriate, effective and coordinated measures are rapidly implemented at European level. As a European leader in pharmaceutical synthesis, SEQENS proposes the following measures to maintain and develop an innovative, competitive and efficient value chain in Europe while relying on existing sites and industrial facilities which could be achieved provided Europe: 1. Support the existing European manufacturers of APIs and intermediates in the on-shoring of essential technologies that will guarantee the supply of the essential medicines. 2. Level the playing field with other world regions to ensure that criteria as important as the security of supply, process safety and respect for the environment are also considered for the purchase of products. Linking the supply of critical supplies to the sole criteria of price cannot be a sustainable supply strategy. Therefore, for EU joint procurement and public tenders, the implementation of sustainable supply practices that comply with European standards in terms of quality, safety and respect for the environment should be imposed. 3. Implement a long-term EU industrial policy that can accelerate sustainable Research, Development and industrialization of innovative and green technologies, as well as manufacturing capacities within the EU territory. The other regions of the world have already launched strong initiatives on the subject of health sovereignty and Europe cannot reasonably stand behind.
Read full response

Meeting with Eszter Batta (Cabinet of Commissioner Thierry Breton)

9 Mar 2021 ยท pharmaceutical strategy, pharmaceutical supply chain resilience, production of APIs